抗流感概念盘中震荡回升，海王生物7连板，沃华医药涨停，欧林生物、粤万年青、北大医药、红日药 业跟涨。 ...

没有虚假记载、误导性陈述或重大遗漏。 特别提示： （一）本次股东会无增加、否决或修改提案的情况。 （二）本次股东会不涉及变更前次股东会决议的情况。 证券代码：002107 证券简称：沃华医药 公告编号：2025-046 山东沃华医药科技股份有限公司 2025 年第四次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 3. 会议召开日期和时间： （1）现场会议：2025 年 11 月 28 日（星期五）14：00 （2）网络投票：通过深圳证券交易所交易系统进行网络投票的 具体时间为 2025 年 11 月 28 日 9:15—9:25，9:30—11:30 和 13:00— 15:00；通过深圳证券交易所互联网投票系统进行网络投票的具体时 一、会议召开和出席情况 （一）会议的召开情况 1. 会议召集人：公司董事会； 2. 会议方式：本次股东会所采用的表决方式是现场表决与网络 投票相结合的方式； 5. 现场会议主持人：副董事长赵彩霞女士； 6. 会议的召集、召开与表决程序符合《公司法》《上市公司股 东会规则》《深圳证券交易所股票上市规则》及《公司章程》等法律、 法规及规范性文件的规定 ...

北京市星河律师事务所 法律意见书 北京市星河律师事务所 关 于 山东沃华医药科技股份有限公司 2025 年第四次临时股东会的 法律意见书 致：山东沃华医药科技股份有限公司 北京市星河律师事务所（以下简称本所）接受山东沃华医药科技股份有限公 司（以下简称贵公司）的委托，就贵公司召开 2025 年第四次临时股东会（以下 简称本次会议）的有关事宜，根据《中华人民共和国公司法》（以下简称《公司 法》）、《中华人民共和国证券法》（以下简称《证券法》）、《上市公司股东 会规则》（以下简称《股东会规则》）及《山东沃华医药科技股份有限公司章程》 （以下简称《公司章程》）的有关规定，出具本法律意见书。 为出具本法律意见书，本所委派律师列席了本次会议。本所律师见证了本次 会议的召开全部过程，并对与本次会议召开有关的文件和事实进行了核查和验 证。 本所律师同意将本法律意见书作为贵公司本次股东会公告文件，随其他应当 公告的文件一起向公众披露，并依法对本所律师发表的法律意见承担法律责任。 本所律师根据《公司法》《股东会规则》《公司章程》的有关规定，按照律 师行业公开的标准，道德规范和勤勉尽责的精神，现就本次会议出具法律意见如 下： 一 ...

Core Viewpoint - The strategic partnership between Shandong Wohua Pharmaceutical Technology Co., Ltd. and Beijing Yicongrong Technology Co., Ltd. aims to enhance the application of Wohua's patented product, Shen Zhi Ling Oral Liquid, in the prevention and treatment of Alzheimer's disease, addressing a significant public health challenge in China [1][2]. Group 1: Alzheimer's Disease Context - Alzheimer's disease is identified as the "fourth leading killer" threatening the health of the elderly, with approximately 16.99 million existing patients and 2.91 million new cases annually in China [1]. - About 75% of Alzheimer's patients do not receive timely diagnosis, leading to a heavy caregiving burden on millions of families [1]. Group 2: Product and Market Potential - Shen Zhi Ling Oral Liquid, developed over 20 years, is based on traditional Chinese medicine and consists of ten herbal ingredients, demonstrating a multi-target intervention mechanism that improves memory and cognitive function in Alzheimer's patients [2]. - The aging population in China is expected to expand the patient base for Alzheimer's disease significantly over the next decade, indicating a high certainty of market growth and substantial "stock conversion" potential due to low current diagnosis rates [2]. Group 3: Strategic Collaboration - The collaboration between Wohua and Yicongrong represents an important exploration of innovative pharmaceutical models, integrating research, market, and service to enhance the clinical value of traditional Chinese medicine [2]. - Wohua will leverage its production quality and academic promotion capabilities, while Yicongrong will utilize its channel resources and patient service advantages to ensure precise market coverage and deep penetration [2]. Group 4: Future Growth and Brand Development - Wohua views Shen Zhi Ling Oral Liquid as a new growth engine, aiming for strategic synergy through accumulated resources in cardiovascular and neurology fields, promoting long-term stable growth [3]. - The partnership is seen as a key initiative to connect Wohua's unique products with professional market platforms, revitalizing the brand image of Shen Zhi Ling Oral Liquid [3].

Core Viewpoint - The strategic cooperation between Shandong Wohuama Pharmaceutical Technology Co., Ltd. and Beijing Yicongrong Technology Co., Ltd. aims to enhance the application of Wohuama's patented product, Shen Zhi Ling Oral Liquid, in the prevention and treatment of Alzheimer's disease, addressing a significant public health challenge in China [1][3][4]. Group 1: Partnership Details - The partnership will integrate research and development, production, clinical promotion, and market channel resources to promote the clinical value of traditional Chinese medicine in managing cognitive disorders [3][4]. - The signing ceremony was attended by key representatives from both companies, indicating a formal commitment to this collaboration [1][3]. Group 2: Alzheimer's Disease Context - Alzheimer's disease is identified as the "fourth leading killer" among the elderly, with approximately 16.99 million existing patients in China and 2.91 million new cases annually [3][4]. - A significant challenge is that about 75% of patients do not receive timely diagnosis, leading to a heavy caregiving burden on families [3][4]. Group 3: Product Overview - Shen Zhi Ling Oral Liquid is a traditional Chinese medicine developed over 20 years, consisting of ten herbal ingredients, and has received multiple national patents and awards [5][6]. - Clinical studies have shown that the product can improve cognitive function and alleviate symptoms associated with Alzheimer's disease, making it suitable for long-term use [6]. Group 4: Market Strategy - The collaboration represents an innovative approach in the pharmaceutical industry, aiming to create a "research-development-market-service" closed loop to enhance the product's market penetration [8]. - Both companies will leverage their respective strengths: Wohuama's production quality and academic promotion, and Yicongrong's channel resources and patient services [8]. Group 5: Economic Impact - The partnership is expected to stimulate regional economic development by providing new opportunities for both companies and enhancing the local biopharmaceutical industry [9]. - The collaboration aligns with national policies aimed at improving Alzheimer's disease prevention and treatment, contributing to the broader goals of "Healthy China" and "Healthy Aging" [9].

Core Insights - The strategic partnership between Wohuamedicine and Yicongrong aims to enhance the application of the patented product, Shen Zhi Ling Oral Liquid, in the prevention and treatment of Alzheimer's disease, thereby increasing the clinical value of traditional Chinese medicine in managing cognitive disorders [1][2][4] Group 1: Alzheimer's Disease Context - Alzheimer's disease poses a significant public health challenge in China, with approximately 16.99 million existing patients and 2.91 million new cases annually, while around 75% of patients do not receive timely diagnosis [2] - National policies, including the "National Action Plan for Dementia (2024-2030)," have been introduced to improve early screening and diagnosis, creating development opportunities for related pharmaceutical products [2] Group 2: Shen Zhi Ling Oral Liquid - Shen Zhi Ling Oral Liquid, developed over 20 years by a team from the Shanghai Institute of Traditional Chinese Medicine, consists of ten herbal ingredients and has received multiple national patents and awards [3] - Clinical studies indicate that Shen Zhi Ling Oral Liquid effectively improves cognitive function and alleviates symptoms associated with Alzheimer's disease, making it the only traditional Chinese medicine approved for this treatment [3] Group 3: Strategic Collaboration - The collaboration represents a significant exploration of innovative pharmaceutical models, aiming to integrate research, market, and service to enhance the product's market presence [4] - Wohuamedicine will leverage its production quality and academic promotion capabilities, while Yicongrong will utilize its marketing and patient service strengths to ensure precise market coverage [4] Group 4: Economic Impact - The partnership is expected to stimulate regional economic development by providing new opportunities for both companies and enhancing the local biopharmaceutical industry [5] - The collaboration aims to contribute to the broader goals of "Healthy China" and "Healthy Aging" by addressing the challenges of Alzheimer's disease through integrated resources and innovative solutions [5]

Core Viewpoint - The divorce settlement between Zhao Bingxian and Lu Juan has resulted in a 50-50 ownership of Zhongzheng Wanrong Investment Group, leading to a governance vacuum for Wohuah Pharmaceutical, which now lacks a controlling shareholder [1] Group 1: Governance Issues - The equal distribution of shares means neither Zhao Bingxian nor Lu Juan can unilaterally control the board or strategic direction, potentially leading to decision-making deadlocks [2] - Key issues such as strategic transformation, major project investments, or executive appointments may become contentious, resulting in governance challenges [2] - Although the company claims that operational management remains unaffected, the dispersed control introduces uncertainty for future stability [2] Group 2: Performance and Growth Concerns - Wohuah Pharmaceutical reported a 179.34% year-on-year increase in net profit for the first three quarters of 2025, primarily driven by non-recurring income from land transfer payments [3] - The core business growth remains weak, with reliance on a limited range of proprietary products amidst increasing regulatory pressures and procurement challenges [3] - The company must address its growth bottlenecks and develop a second growth curve to ensure long-term sustainability [3] Group 3: Industry-Wide Implications - Wohuah Pharmaceutical is not an isolated case; several other companies have faced similar issues due to controlling shareholders' divorces, leading to significant ownership restructuring [4] - These events have raised concerns about the stability of shareholder structures and the management of risks associated with controlling shareholders' personal relationships [4] - As the capital market matures, it is crucial to implement measures such as corporate governance design, equity trusts, and voting rights arrangements to mitigate disruptions caused by personal relationship changes [4] Conclusion - The "no owner" status of Wohuah Pharmaceutical highlights broader governance challenges within A-share companies, emphasizing the need for strategic resilience and operational stability in the face of high volatility and uncertainty in ownership structures [5]

Core Viewpoint - Wohuah Pharmaceutical's stock has shown a significant increase of 42.06% year-to-date, with a recent price of 6.62 CNY per share, indicating strong market interest and performance [1][2]. Company Overview - Wohuah Pharmaceutical, established on February 9, 2002, and listed on January 24, 2007, specializes in the research, production, and sales of natural plant-based cardiovascular traditional Chinese medicine [1]. - The company's revenue composition includes 69.17% from cardiovascular drugs, 23.46% from musculoskeletal drugs, 3.59% from other categories, 2.97% from antiviral respiratory drugs, and 0.81% from reproductive and urinary system drugs [1]. Financial Performance - For the period from January to September 2025, Wohuah Pharmaceutical reported a revenue of 625 million CNY, reflecting a year-on-year growth of 8.31%, and a net profit attributable to shareholders of 63.995 million CNY, which is a substantial increase of 179.34% year-on-year [2]. - The company has distributed a total of 692 million CNY in dividends since its A-share listing, with 214 million CNY distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, Wohuah Pharmaceutical had 41,000 shareholders, an increase of 17.18% from the previous period, with an average of 13,892 circulating shares per shareholder, down by 14.66% [2]. - Notable new institutional shareholders include Baodao Jiuhang Mixed A and Guotai Haitong CSI 500 Index Enhanced A, which are now among the top ten circulating shareholders [3].

Core Viewpoint - Wohuah Pharmaceutical announced the convening of its sixth temporary board meeting of the eighth session on November 12, 2025, to discuss the proposal for the fourth temporary shareholders' meeting of 2025 [1] Group 1: Company Financials - For the first half of 2025, Wohuah Pharmaceutical's revenue composition was 100.0% from the pharmaceutical industry [1] - The current market capitalization of Wohuah Pharmaceutical is 3.7 billion yuan [1]

证券代码：002107 证券简称：沃华医药 公告编号：2025-044 山东沃华医药科技股份有限公司 关于拟变更会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带责任。 重要内容提示： 1、拟聘任的会计师事务所：中喜会计师事务所（特殊普通合伙） （以下简称中喜会计师事务所）。 2、原聘任的会计师事务所：永拓会计师事务所（特殊普通合伙） （以下简称永拓会计师事务所）。 3、拟变更会计师事务所的原因：山东沃华医药科技股份有限公 司（以下简称公司）根据自身业务发展及整体审计工作需要，综合考 虑公司经营管理实际，根据相关规定，公司拟聘任中喜会计师事务所 为公司2025年度财务报告及内部控制的外部审计机构。 4、公司已就变更会计师事务所的相关事宜与前后任会计师事务 所进行了沟通，前后任会计师事务所已明确知悉本次变更事项并确认 无异议。公司董事会、审计委员会对本次拟变更审计机构的事项均不 存在异议，该事项尚需提交公司股东会审议。 5、公司拟变更会计师事务所符合财政部、国务院国资委、证监 1 会印发的《国有企业、上市公司选 ...